Welcome to our dedicated page for Invizyne Technologies news (Ticker: IZTC), a resource for investors and traders seeking the latest updates and insights on Invizyne Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Invizyne Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Invizyne Technologies's position in the market.
Invizyne Technologies (NASDAQ: IZTC) has been awarded a $2 million project from the U.S. Department of Defense's BioMADE initiative to advance sustainable aviation fuel (SAF) capabilities. The project, in partnership with the University of Georgia, focuses on enabling enzyme production for cell-free biomanufacturing of isobutanol, a key SAF precursor. This follows previous grants totaling $5.85 million from the Department of Energy. The project aims to develop an enzyme production pipeline and deploy technology in 100L pilot-scale facilities. The global SAF market is projected to grow at 52.2% annually, reaching $27.4 billion by 2032.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced the closing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share. Trading began on NASDAQ under symbol IZTC on November 13, 2024. The IPO raised approximately $15 million in gross proceeds. The company granted a 45-day option to the underwriter to purchase up to 281,250 additional shares. Additionally, in a concurrent private placement, Invizyne issued 93,750 warrants at $0.125 each, exercisable at $8.00 per share for five years.
Invizyne Technologies (NASDAQ:IZTC), a designer of cell-free, enzyme-based biomanufacturing systems, began trading on Nasdaq on Nov. 13, 2024. The company, founded in 2019, is based on technology developed by UCLA Professor Emeritus James Bowie that enables enzymatic pathways to function outside living cells. CEO Michael Heltzen emphasized the company's ability to overcome traditional cell-based synthetic biology limitations through their next-generation enzymes and biomanufacturing platform, aiming to demonstrate commercial viability through licensing deals and partnerships.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the Nasdaq Capital Market on November 13, 2024, under the ticker symbol 'IZTC'. The company, which focuses on producing commercially important molecules and chemicals for everyday life, expects the offering to close on November 14, 2024, subject to customary closing conditions.
Invizyne Technologies has announced the pricing of its Initial Public Offering of 1,875,000 common stock shares at $8.00 per share, raising $15 million in gross proceeds. Trading will begin on Nasdaq under ticker 'IZTC' on November 12, 2024. The company granted a 45-day over-allotment option for 281,250 additional shares and will issue 184,375 warrants in a concurrent private placement. Proceeds will fund production expansion, business development, sales and marketing, loan repayment, and working capital. The offering is expected to close on November 13, 2024, with MDB Capital acting as underwriter.
FAQ
What is the current stock price of Invizyne Technologies (IZTC)?
What is the market cap of Invizyne Technologies (IZTC)?
